sis of myeloma ,AnnuaI review of pathology 6:249-274.
[0344] Belmadani，S·，J·Bernal，C·C.Wei，M.A.Pallero，L.Dell' italia，J.E.Murphy-Ullrich and K.H.Berecek(2007).thrombospondin-lantagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II.^Am J Pathol 171(3):777-789.
[0345] BreitkopfjK.,I.SawItzajJ-H-Westhoff jL.WickertjS.Dooley and A.M.Gressner(2005).^Thrombospondin lacts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.'Gut 54(5):673-681.
[0346] Carron，J.A.，C.A.Walsh，W.D.Fraser and J.A.Gallagher(1995)·" Thrombospondin promotes resorption by osteoclasts in vitro ,Biochem Biophys Res Commun 213(3):1017-1025.
[0347] Cauchard,J.H.,A-BertonjG-GodeaujW-Hornebeck and G.BeIIon(2004).^ Activation of latent transforming growth factor beta I and inhibition of matrix metalloprotease activity by a thrombospondin-like tripeptide linked to elaidic acid,Biochemical pharmacology 67(11):2013-2022.
[0348] Chen，Y·，A·Leask，D·J·Abraham，L·Kennedy，X·Shi-Wen，C·P·Denton，C·M·Black， L.S.Verjee and M.Eastwood(2011).^Thrombospondin I is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase(MEK)/extracellular signal-regulated kinase(ERK)-dependent mechanism.^Fibrogenesis&tissue repair 4(1):9.
[0349] Chen，Y.，X.Wang，D.Weng，L.Tian，L.Lv，S.Tao and J.Chen(2009)."A TSP-I synthetic peptide inhibits bleomycin-induced lung fibrosis in mice. Experimental and Toxicologic Pathology 61(1):59-65.
[0350] Chipev，C.C.，R.Simman，G.Hatch，A.E.Katz，D.M.Siegel and M.Simon(2000)·" Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro.'Cell Death Differ 7(2):166-176.
[0351 ] ConnolIy，E·C·，E·F·Saunier，D.Quigley，M.T.Luu，A·De Sapio，B·Hann， J.M.Yingling and R.J.Akhurst(2011).^Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761."Cancer research71(6):2339-2349.
[0352] Crawford,S.E.,V.Stellmach,J.E.Murphy-Ullrich,S.M.Ribeiro,J. Lawler, R.0.Hynes，G.P.Boivin and N.Bouck(1998) ,Thrombospondin-1 is a major activator of TGF-betal in vivo."Cell 93(7):1159-1170.
[0353] Daniel，C.，K.Schaub，K.Amann，J.Lawler and C.Hugo(2007)·"Thrombospondin-I is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo."Diabetes 56(12):2982-2989·
[0354] Daniel,C.,Y.Takabatake,M.Mizui,Y.IsakajH-Kawashi,H-Rupprecht jE.Imai and C.Hugo(2003) ·''Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo,Am J Pathol 163(3):1185-1192.
[0355] Daniel,C.,J.ffiede,H.C.Krutzsch,S.M.Ribeiro,D.D.Roberts ,J.E.Murphy-Ullrich and C.Hugo(2004).^Thrombospondin-I is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo ·''Kidney international 65(2) :459-468.
[0356] Derks,R.A.,E.Jankowska-Gan,Q.Xu and ff.J.Burlingham(2007).^Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1·''Journal of immunology 179(6):3443-3451.
[0357] Diop-Frimpong，B·，V.P·Chauhan，S.Krane，Y.Boucher and R.K.Jain(2011)·" Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors·"Proceedings of the National Academy of Sciences of the United States of America 108(7):2909-2914.
[0358] DiPietro，L.A.，N.N.Nissen，R.L.Gamelli，A.E.Koch，J.M.Pyle and P · J · Pol verini (1996) ·''Thrombospondin I synthesis and function in wound repair."Am J Pathol 148(6):1851-1860.
[0359] DongjM.and G.C.Blobe(2006).^Role of transforming growth factor-beta in hematologic malignancies ,Blood 107(12):4589-4596.
[0360] Flavell，R.A.，S·Sanjabi，S·Η·Wrzesinski and P·Licona_Limon(2010)·"The polarization of immune cells in the tumour environment by TGFbeta·"Nature reviews. Immunology 10(8):554-567.
[0361 ] Futagami，Y.，S·Sugita，J.Vega，K.Ishida，H.Takase，K.Maruyama，H.Aburatani and M.Mochizuki(2007).^Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells.Immunol 178(11):6994-7005.
[0362] Harpel, J . G . , S . Schultz-Cherry , J. E . Murphy-Ullrich and D.B.Rifkin (2001).^Tamoxifen and estrogen effects on TGF-beta formation: role of thrombospondin-1 ,alphavbeta3 ,and integrin-associated protein ·''Biochemical and biophysical research communications 284(1):11-14.
[0363] Hayashi,T. ,T-HideshimajA-N.Nguyen ,0. Munoz ,K.Podar,M.Hamasaki, K.Ishitsuka，H.Yasui，P.Richardson，S.Chakravarty，A.Murphy，D.Chauhan，L.S.Higgins and K.C.Anderson(2004).^Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.^Clin Cancer Res 10(22):7540-7546.
[0364] Hugo，C.(2003)·"The thrombospondin 1-TGF-beta axis in fibrotic renal disease,Nephrol Dial Transplant 18(7):1241-1245.
[0365] IsufijI.,M.Seetharam,L. Zhou ,D.Sohal,J.Opalinska,P.Pahanish and A·Verma(2007)·"Transforming growth factor-beta signaling in normal and malignant hematopoiesis·"Journal of interferon&cytokine research:the official journal of the International Society for Interferon and Cytokine Research 27 (7):543-552.
[0366] J〇u，I.M.，A.L.Shiau，S.Y.Chen，C.R.Wang，D.B.Shieh，C.S.Tsai and C.L.Wu (2005) ·''Thrombospondin I as an effective gene therapeutic strategy in collagen-induced arthritis ,Arthritis Rheum 52(1):339-344.
[0367] K · Bai I ey DuBose，M · Zay zaf oon and J · E · Murphy-Ul Ir i ch ( 20 I 2 ) ·" Thrombospondin-I inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF-beta activation·"Biochemical and Biophysical Research Communications 422(3):488-493.
[0368] Kondou,H.,S.Mushiake,Y.Etani,Y.MiyoshijT.Michigarni and K.Ozono (2003) ,A blocking peptide for transforming growth factor-betaIactivation prevents hepatic fibrosis in vivo·''Journal of hepatology 39(5) :742-748.
[0369] KukrejajA.,S-RadfarjB-H.Sun jK.Insogna and M.V.Dhodapkar(2009).^ Dominant role of CD47-thrombospondin_l interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease·''Blood 114(16):3413-3421.
[0370] Lanz，T.V.，Z.Ding，P.P.Ho，J.Luo，A·N·Agrawal，H·Srinagesh，R·AxtelI， H.Zhang,M.Platten,T.Wyss-Coray and L.Steinman(2010).^Angiotensin II sustains brain inflammation in mice via TGF-beta·"The Journal of clinical investigation 120(8):2782-2794.
[0371] LiujS.,L.Shi and S.Wang(2007).^Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury.''American journal of physiology.Renal physiology 293(5):Fl727-1735.
[0372] Longo，V·，0·Brunetti，S·D'Oronzo，F·Dammacco and F·Silvestris(2012)·" Therapeutic approaches to myeloma bone disease: An evolving story·"Cancer treatment reviews.
[0373] Lu，A·，M.Miao，T·R·Schoeb，A·Agarwal and J·E·Murphy-Ullrich(2011)·" Blockade of TSPl-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy·"The American journal of pathology 178(6):2573-2586.
[0374] Ludlow,A.,K.0.YeejR.Lipman,R.Bronson,P.Weinreb,X.Huang,D. Sheppard and J·Lawler(2005)· ''Characterization of integrin beta6 and thrombospondin-1 double-null mice.〃J Cell Mol Med 9(2):421-437.
[0375] Matsumoto，T·and M·Abe(2011)·"TGF-beta-related mechanisms of bone destruction in multiple myeloma."Bone 48(1):129-134.
[0376] Miao，W.M·，W.L·Seng，M.Duquette，P·Lawler，C.Laus and J·Lawler(2001)·" Thrombospondin-I type I repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and-independent mechanisms."Cancer Res 61(21):7830-7839.
[0377] Mimura,Y.,H-IhnjM-JinninjY.Asano,K.Yamane and K·Tamaki(2005), Constitutive thrombospondin-I overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts."Am J Pathol 166(5):1451-1463.
[0378] Morishima，Y.，A.Nomura，Y·Uchida，Y.Noguchi，T·Sakamoto，Y.Ishii，Y.Goto， K.Masuyama,M.J.ZhangjK.Hirano,M.Mochizuki,M.Ohtsuka and K.Sekizawa(2001).^ Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding ,American journal of respiratory cell and molecular biology 24(1):1-11·
[0379] Murphy-Ullrich，J.E.and D.F.Mosher(1985)·"Localization of thrombospondin in clots formed in situ,Blood 66(5):1098-1104.
[0380] Murphy-UllrichjJ.E.and M.Poczatek(2000).^Activation of latent TGF-beta by thrombospondin-1!mechanisms and physiology.^Cytokine&growth factor reviews 11(1-2):59-69.
[0381 ] Myung，S·J·，J·H.Yoon，G·Y·Gwak，W·Kim，J·I·Yang，S.H.Lee，J.J.Jang and H. S·Lee(2007)·〃Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor-beta-dependent hepatic stellate cell activation.^Biochem Biophys Res Commun 353(4):1091-1096·
[0382] NaitojT.,T.Masaki,D-J-Nikolic-Paterson jC-Tanji,N.Yorioka and N.Kohno (2004)·"Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK:a mechanism for activation of latent TGF-betal, American journal of physiology.Renal physiology 286(2):F278-287.
[0383] Noonan，K.，L.Marchionni，J.Anderson，D.Pardoll，G.D.Roodman and I. BorrelIo(2010).novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.^Blood 116(18):3554-3563.
[0384] Nor,J.E. ,L.Dipietro,J.E.Murphy-Ul Iri ch,R.0. Hynes ,J. Lawler and P.J.PoIverini(2005).^Activation of Latent TGF-betal by Thrombospondin-1 is a Major Component of Wound Repair ·''Oral biosciences&medicine:OBM 2(2): 153-161.
[0385] Pierson，B·A·，K·Gupta，W·S·Hu and J·S·MiIIer(1996)·"Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta I and independent accessory cell-derived contact and soluble factors."Blood 87(1):180-189.
[0386] Poczatek,M.H.,C.Hugo,V.Darley-Usmar and J.E.Murphy-Ullrich(2000).^ Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1.^Am J Pathol 157(4):1353-1363.
[0387] Pohlers，D·，A·Beyer，D·Koczan，T·Wilhelm，H·J·Thiesen and R·W·Kinne (2007)·''Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts·"Arthritis research& therapy 9(3):R59.
[0388] PourjL.,H.SvachovajZ-Adam jM-Almasi,L-BuresovajT-BuchlerjL-Kovarova j P-NemecjM-PenkajJ-Vorlicek and R.Hajek(2010).^Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response ,Annals of hematology 89(4):385-389.
[0389] Prabhala，R.H.，D.Pelluru，M.Fulciniti，Η·Κ·Prabhala，P.Nanjappa，W.Song， C.PaijS.AminjY-T-TaijP-G.Richardson , I.M.Ghobrial,S.P.TreorijJ.F.Daley, K.C.Anderson,J.L.Kutok,et al.(2010).^Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma."Blood 115(26):5385-5392·
[0390] Prud'homme，G·J·(2007)·"Pathobiology of transforming growth factor beta in cancer ,fibrosis and immunologic disease，and therapeutic considerations· ''Laboratory investigation;a journal of technical methods and pathology 87(11):1077-1091.
[0391] Raugi，G.J.，J.E.01erud and A.M.Gown(1987)·"Thrombospondin in early human wound tissue,J Invest Dermatol 89(6):551-554.
[0392] Reed ,M.J.,P.Puolakkainen,T.F. Lane,D-Dickerson